Many patients present with advanced stage HL.44 In the 1960s, DeVita and colleagues from the National Cancer Institute (NCI) introduced a multiagent chemotherapy regimen known as MOPP that established cure in over 50% of patients with advanced disease.45 Before this era, 5-year survival from advanced HL barely reached 5%. However, MOPP had significant short- and long-term toxicities. Investigators subsequently examined other regimens, such as ABVD. ABVD yields similar survival rates as MOPP but has fewer short- and long-term toxicities. What follows is a brief review of the historical development of chemotherapy regimens for advanced HL, a discussion of the "new" regimens used for higher-risk patients, and an examination of the role of radiation therapy as part of CMT in the advanced disease setting.

0 0

Post a comment